* 1. presence of fever within 72 hours before the study vaccination (for participants \>14 years old, axillary temperature ≥37.3℃; for participants ≤14 years old, axillary temperature ≥37.5℃;); * 2. a positive result of antigen test or nucleic acid test for sars-cov-2 during the screening period; * 3. a positive result of sars-cov-2 igm test; * 4. known history of sars-cov-2 infection within 6 months before icf; * 5. a history of sereve allergic reactions such as severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema, or allergic reactions to the study vaccines and its ingredient; * 6. a medical or family history of seizure, epilepsy and psychosis; * 7. participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis; * 8. contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders; * 9. patients on antituberculosis therapy; * 10. participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination; * 11. participants who received other investigational drugs within 1 month before the study vaccination; * 12. participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study; * 13. those who donated blood or had blood loss (≥450 ml) within 3 months before the vaccination or plan to donate blood during the study period; * 14. those who are pregnant or breast-feeding or plan to be pregnant during the study period; * 15. those who plan to donate ovum or sperms during the study period; * 16. those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing; * 17. those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants.

* 1. presence of fever within 72 hours before the study vaccination (for participants \>14 years old, axillary temperature ≥37.3℃; for participants ≤14 years old, axillary temperature ≥37.5℃;); * 2. a positive result of antigen test or nucleic acid test for sars-cov-2 during the screening period; * 3. a positive result of sars-cov-2 igm test; * 4. known history of sars-cov-2 infection within 6 months before icf; * 5. a history of sereve allergic reactions such as severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema, or allergic reactions to the study vaccines and its ingredient; * 6. a medical or family history of seizure, epilepsy and psychosis; * 7. participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis; * 8. contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders; * 9. patients on antituberculosis therapy; * 10. participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination; * 11. participants who received other investigational drugs within 1 month before the study vaccination; * 12. participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study; * 13. those who donated blood or had blood loss (≥450 ml) within 3 months before the vaccination or plan to donate blood during the study period; * 14. those who are pregnant or breast-feeding or plan to be pregnant during the study period; * 15. those who plan to donate ovum or sperms during the study period; * 16. those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing; * 17. those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants.

1. presence of fever within 72 hours before the study vaccination (for participants >14 years old, axillary temperature ≥37.3℃; for participants ≤14 years old, axillary temperature ≥37.5℃;); 2. a positive result of antigen test or nucleic acid test for sars-cov-2 during the screening period; 3. a positive result of sars-cov-2 igm test; 4. known history of sars-cov-2 infection within 6 months before icf; 5. a history of sereve allergic reactions such as severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema, or allergic reactions to the study vaccines and its ingredient; 6. a medical or family history of seizure, epilepsy and psychosis; 7. participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis; 8. contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders; 9. patients on antituberculosis therapy; 10. participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination; 11. participants who received other investigational drugs within 1 month before the study vaccination; 12. participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study; 13. those who donated blood or had blood loss (≥450 ml) within 3 months before the vaccination or plan to donate blood during the study period; 14. those who are pregnant or breast-feeding or plan to be pregnant during the study period; 15. those who plan to donate ovum or sperms during the study period; 16. those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing; 17. those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants.

1. presence of fever within 72 hours before the study vaccination (for participants >14 years old, axillary temperature ≥37.3℃; for participants ≤14 years old, axillary temperature ≥37.5℃;); 2. a positive result of antigen test or nucleic acid test for sars-cov-2 during the screening period; 3. a positive result of sars-cov-2 igm test; 4. known history of sars-cov-2 infection within 6 months before icf; 5. a history of sereve allergic reactions such as severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema, or allergic reactions to the study vaccines and its ingredient; 6. a medical or family history of seizure, epilepsy and psychosis; 7. participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis; 8. contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders; 9. patients on antituberculosis therapy; 10. participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination; 11. participants who received other investigational drugs within 1 month before the study vaccination; 12. participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study; 13. those who donated blood or had blood loss (≥450 ml) within 3 months before the vaccination or plan to donate blood during the study period; 14. those who are pregnant or breast-feeding or plan to be pregnant during the study period; 15. those who plan to donate ovum or sperms during the study period; 16. those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing; 17. those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants.